Latest News and Press Releases

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies...

Alvotech (NASDAQ: ALVO) tekur þátt í árlegri heilbrigðisráðstefnu Jefferies fjárfestingabankans í New York sem haldin verður dagana 3.-5. júní nk. Fulltrúar félagsins funda með einstökum fjárfestum og...

REYKJAVIK, Iceland, June 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programsThe agreement includes proposed biosimilars to...

Samningurinn felur í sér greiðslu við undirritun og áfangagreiðslur, samtals að upphæð allt að 23,1 milljarður króna (160 milljónir evra), en að auki munu samstarfsaðilarnir skipta með sér tekjum af...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programsThe agreement includes proposed biosimilars to...

The Annual General Meeting of Alvotech will be held on Wednesday June 25, 2025, at 09.00 a.m. CEST at the premises of Arendt & Medernach at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand...

Aðalfundur Alvotech verður haldinn miðvikudaginn 25. júní 2025, kl. 09.00 CEST á skrifstofu Arendt & Medernach að 41A Avenue John F. Kennedy, L-1855 Lúxemborg. Dagskrá fundarins er að finna í...

Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition...

Í viðhengi er tilkynning um viðskipti stjórnenda og tengdra aðila sem lögð var inn til birtingar hjá fjármálaeftirliti Lúxemborgar, Luxembourg Commission de Surveillance du Secteur Financier (CSSF),...